Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688597 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
A Phase 2 study, sponsored by Amicus Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00688597 is a Phase 2 study that was terminated before completion, run by Amicus Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT00688597, a Phase 2 study, was terminated before completion, sponsored by Amicus Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main purpose of this study was to determine the safety and tolerability of 3 different doses of duvoglustat (AT2220) in participants affected by Pompe disease. The study also evaluated the effects of duvoglustat on functional parameters in Pompe disease.
Interventions
- DRUG Duvoglustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-12-08 |
| Est. Completion | 2009-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688597
The ClinicalTrials.gov registry entry for NCT00688597 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duvoglustat is the first listed.
NCT00688597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688597 about?
NCT00688597 is a clinical study titled "Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease". The main purpose of this study was to determine the safety and tolerability of 3 different doses of duvoglustat (AT2220) in participants affected by Pompe disease. The study also evaluated the effects of duvoglustat on functional parameters in Pompe disease.
What is the current status of trial NCT00688597?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2008-12-08. Estimated completion is 2009-12-14.
What interventions are being tested in trial NCT00688597?
The interventions under investigation include: Duvoglustat (DRUG).
Who is sponsoring clinical trial NCT00688597?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.